These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 9330930

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Bayesian calculation of methotrexate clearance after low dose intramuscular administration in patients with rheumatoid arthritis.
    Monjanel-Mouterde S, Lafforgue P, Blanc A, Catalin J, Aquaviva PC, Durand A.
    J Rheumatol; 1998 Jul; 25(7):1276-81. PubMed ID: 9676756
    [Abstract] [Full Text] [Related]

  • 3. Is there an optimal time to administer methotrexate in the treatment of rheumatoid arthritis?
    Carpentier N, Bertin P, Marquet P, Sabot C, Bonnet C, Debord J, Lachâtre G, Trèves R.
    J Rheumatol; 1998 Jul; 25(7):1270-5. PubMed ID: 9676755
    [Abstract] [Full Text] [Related]

  • 4. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis.
    Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC.
    J Rheumatol; 1995 May; 22(5):844-9. PubMed ID: 8587070
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis.
    Gumbhir-Shah K, Cevallos WH, DeCleene SA, Korth-Bradley JM.
    J Rheumatol; 1996 Jun; 23(6):984-9. PubMed ID: 8782127
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
    Anaya JM, Fabre D, Bressolle F, Bologna C, Alric R, Cocciglio M, Dropsy R, Sany J.
    J Rheumatol; 1994 Feb; 21(2):203-8. PubMed ID: 8182625
    [Abstract] [Full Text] [Related]

  • 9. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.
    Debord J, Carpentier N, Sabot C, Bertin P, Marquet P, Treves R, Merle L, Lachâtre G.
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):227-30. PubMed ID: 9587050
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V.
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.
    Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M.
    J Rheumatol; 2004 Apr; 31(4):645-8. PubMed ID: 15088287
    [Abstract] [Full Text] [Related]

  • 15. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group.
    J Rheumatol; 1995 Feb; 22(2):218-23. PubMed ID: 7738941
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of low-dose methotrexate in adult asthmatics.
    Glynn-Barnhart AM, Erzurum SC, Leff JA, Martin RJ, Cochran JE, Cott GR, Szefler SJ.
    Pharmacotherapy; 1992 Feb; 12(5):383-90. PubMed ID: 1437699
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months.
    Kremer JM, Petrillo GF, Hamilton RA.
    J Rheumatol; 1995 Jan; 22(1):41-4. PubMed ID: 7699679
    [Abstract] [Full Text] [Related]

  • 19. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.
    Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Frampton C, James J, Barclay ML.
    Arthritis Rheum; 2009 Aug; 60(8):2248-56. PubMed ID: 19644853
    [Abstract] [Full Text] [Related]

  • 20. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
    Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS.
    J Rheumatol; 1999 Dec; 26(12):2539-43. PubMed ID: 10606360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.